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There are several molecular entities common to the immune and nervous systems. Salient among them are
the chemokines and their receptors, which play remarkably varied and potent roles in immunobiology and
neurobioloogy. This review limns several illustrative examples and presents general principles of chemokine
action that are manifest in both systems. These include the following: (1) chemokines tend equally to arrest
cells and to make them move, in the process of positioning target cells with spatiotemporal precision; (2)
signaling and nonsignaling receptors collaborate to adjust the chemokine environment for maximal efficacy;
and (3) expression of a single chemokine receptor on circulating blood cells and parenchymal cells is often
used to coordinate complex tissue responses. The challenge is to integrate knowledge of the roles of key
receptors (as well as their ligands) into a coherent account of events during pathologic processes, in order
to guide therapeutic development.Classification and Organization of the Chemokine
System
The immune and nervous systems comprise a number of mole-
cules shared in common. Such findings were not unexpected
given the complexity of the immune and nervous systems, but
the specific molecules and processes involved have often
been fascinatingly surprising. Chemokines and their receptors
are prominent examples of joint use by the immune and nervous
systems, yet seemed initially to be completely devoted to assist-
ing the function of the immune system.
The chemokine universe is comprised of approximately 50
peptides and 20 receptors in humans, with homologs, orthologs,
and related peptides in other vertebrate species (Charo and Ran-
sohoff, 2006; Rot and von Andrian, 2004). Chemokines are
divided into families and signal to corresponding families of che-
mokine receptors (for example, CXC chemokine action is medi-
ated by CXC chemokine receptors). Chemokine receptors are G
protein-coupled receptors (GPCRs) and act specifically through
pertussis toxin-sensitive Gai components. Chemokine-specific
GPCRs are drug targets, and the biotechnology and pharmaceu-
tical industry hasmountedsubstantial efforts tomodulatechemo-
kine receptor activity, heightening the medical importance of
understanding how chemokines regulate inflammatory disease.
First identified by their ability to mediate leukocyte chemoattrac-
tion in vitro, chemokines are now recognized to govern a wide
array of leukocyte functions during inflammation and immunity.
The numerical mismatch between chemokines and receptors
makes it apparent that ligand-receptor relationships may not be
simple, and this suspicion has proven to be accurate (Rot and
von Andrian, 2004). Several chemokine-receptor pairs are exclu-
sive; for other chemokine receptors, responses can be elicited
by as many as 10 individual ligands. Conversely, some chemo-
kines can productively signal to as many as three receptors.
There have been several excellent reviews detailing ligand-receptor relationships (Bacon et al., 2002; Zlotnik and Yoshie,
2000; Rot and von Andrian, 2004; Bonecchi et al., 2009).
Chemokines deliver diverse and context-specific signals. The
remarkable versatility and functional flexibility of the chemokine
system is conferred by (1) their large number; (2) their tightly
regulated transcriptional expression; (3) their ability to interact
with binding moieties (such as glycosaminoglycans or non-
signaling receptors) after secretion; and (4) their proteolytic
processing (Ransohoff, 2003). Lending further plasticity for regu-
lated expression, chemokine genes can be subject to copy-
number polymorphism. Chemokine expression, particularly
during inflammation, is primarily regulated by inducible tran-
scription, followed by translation, secretion, and turnover. How-
ever, two chemokines (CXCL16; CX3CL1) are expressed as
transmembrane components that are regulated by cleavage by
members of the ADAM (a disintegrin and metalloprotease) family
enzymes, at least for action at a distance as soluble chemoat-
tractants. Membrane-bound CX3CL1 and CXCL16 can also
serve as adhesion molecules for receptor-bearing cells.
The chemokine ligand super-family is further partitioned into
subgroups of the largest (CC chemokines; 28 members) and
second largest (CXC chemokines; 16 members) families.
Genomic organization helps to give order to this large super-
family (Colobran et al., 2007). Most human CXC chemokines
are encoded at chromosomal location 4q12-21, with themajority
of CC chemokine found at 17q11-21, and these loci are often
syntenic in other mammalian species. Chemokine subgroup
members, encoded in multigene arrays, are functionally related.
For example, CXCL9, CXCL10, and CXCL11 are three CXC-
family, IFN-g-inducible chemokines. These chemokines signal
to a single receptor CXCR3 (which is regulated by the Th1 cell-
associated transcription factor T-bet) and are clustered together
separated by at most a few dozen kilobases. A similar array
contains eosinophil-attracting eotaxin peptides CCL24 andImmunity 31, November 20, 2009 ª2009 Elsevier Inc. 711
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Figure 1. Chemokine Receptor Signaling
Mediates Arrest of Moving Cells in the
Immune and Nervous Systems
The cartoon illustrates the function of chemokine
receptor signaling in the early phases of leukocyte
extravasation under flow. Initial leukocyte-endo-
thelial interactions are loose and reversible. Che-
mokines are immobilized in the vascular lumen by
interactions with glycosaminoglycans or by pre-
sentation through molecules such as the Duffy
antigen receptor for chemokines (DARCs). Che-
mokine receptor signaling converts inactive integ-
rin to active integrin, capable of high-affinity inter-
action with cell-adhesion molecules (CAMs) on
the endothelial luminal surface. This interaction
arrests the leukocyte under flow and extravasation
of the leukocyte often follows. The lower panel
shows an oligodendrocyte precursor cell (OPC)
moving through the presumptive white matter of
the postnatal rodent spinal cord. Chemokine
CXCL1 is expressed focally in these tissues and
signals to CXCR2 on the OPC. In an in vitro model,
signaling through CXCR2 leads to increased inter-
action between theOPC and a laminin substrate. Studies with purifiedOPCs in vitro, and in vivo analysis ofCxcr2/mice, suggest that arrest of theOPC in a high
local concentration of CXCL1 and PDGF (which is present throughout the developing spinal cord) drives a burst of OPC proliferation.CCL26, which are members of the CC family. ‘‘Solitary’’ chemo-
kines, such as CXCL12 at Chr.10q11 and CXCL16 at 17p13
found outside multigene arrays, are noted to be paired exclu-
sively with individual signaling receptors and to have distinct
functions. With respect to CXCL9, CXCL10, and CXCL11, even
though their genomic, structural, and in vitro functional similari-
ties give an appearance of conspicuous redundancy, careful
analysis of cells expressing engineered receptors demonstrated
selective signaling pathways suggesting distinct functions (Col-
vin et al., 2004). This concept was confirmed with the demon-
stration that CXCL9 played a crucial and nonredundant role in
antitumor immunity (Gorbachev et al., 2007). Not surprisingly,
the role of CXCR3 in T cell trafficking during Th1 cell immune
responses has proven surprisingly subtle and intricate (Koch
et al., 2009; Lord et al., 2005; Liu et al., 2005, 2006b). It is accord-
ingly accurate to speak both of redundancy and specificity in the
chemokine system (Mantovani, 1999; Charo and Ransohoff,
2006; Rot and von Andrian, 2004).
Chemokines Regulate Cell-Cell Interactions
The eponymous action of chemokines toward responsive cells is
gradient-dependent chemoattraction in vitro. It seems intuitively
appealing to assign chemokines a role in leukocyte trafficking
based purely on their ability to drive gradient-dependent migra-
tion; this notion, however, is incomplete. Rather, chemokine
action causes cells initially to arrest, rather than move (Fig-
ure 1), during the multistep process of leukocyte extravasation
(Butcher, 1991) under flow (Alon et al., 2003; Alon and Feigelson,
2002; Cinamon et al., 2001a, 2001b, 2004; Laudanna and Alon,
2006; Schreiber et al., 2007; Ransohoff et al., 2007). Perhaps
most importantly, chemokines mediate both clustering and
conformational changes of integrins, leading to high-affinity
and -avidity integrin interactions with cell adhesion molecules
(CAMs) on vascular endothelial cells.
Chemokine-chemokine receptor signaling (or action through
closely related chemoattractant receptors) is therefore essential
for leukocyte-endothelial recognition, which regulates leukocyte
trafficking. Leukocyte extravasation requires multiple chemo-712 Immunity 31, November 20, 2009 ª2009 Elsevier Inc.kine-mediated signals. As noted above, the first signal, delivered
by chemokines immobilized on the luminal surface of the endo-
thelial cell, helps convert leukocyte rolling under flow on endo-
thelium into arrest, by inducing Rho GTPase family signaling
that causes conformational change and redistribution of leukoin-
tegrins (Ward, 2009). These alterations in their shape and distri-
bution are required for firm adhesion of leukocyte integrins (such
as LFA-1) to CAMs (such as ICAM-1) on endothelium (Shulman
et al., 2009). Additional chemokine signals are implicated in
‘‘crawling’’ of leukocytes across endothelium in search of a suit-
able locus for extravasation. Finally, chemokines are implicated
in extravasation itself through inducing cytoskeletal reorganiza-
tion and chemotaxis toward abluminal chemokines in inflamed
tissues. In one classic example, CCL21 is an arrest receptor for
lymphocytes rolling on high endothelial venules (HEV) of periph-
eral lymph nodes (Stein et al., 2000). In the context of leukocyte
trafficking, chemokines and their receptors are grouped as
homeostatic (chemokines expressed constitutively in organs
such as in lymph nodes and spleen, with receptors on leukocytes
homing to those organs) or inflammatory (chemokines induced
on-demand at sites of inflammation, with cognate receptors on
infiltrating leukocytes) (Charo and Ransohoff, 2006).
As predicted, gene targeting studies showed that inflamma-
tory chemokine receptors such as CCR2 and CXCR2 are essen-
tial for responses to a wide variety of infectious and inflammatory
challenges (Charo and Ransohoff, 2006). Studies of the homeo-
static chemokine receptors such as CCR7 and CXCR5 led to
a paradigm refinement (if not shift): in early gene-targeting exper-
iments, CXCR5 (Forster et al., 1996), and later CCR7, were impli-
cated in developmental organogenesis for lymphoid tissues, as
well as in lymphocyte homing to lymph nodes (Lipp and Muller,
2003). These striking findings showed chemokine receptors
mediated cell migration during development, as well as during
inflammatory and immune processes in the postnatal organism.
Nonsignaling Chemokine Receptor-like Molecules
Considerable effort seems to have been devoted tomaintenance
of appropriate fluid and tissue amounts of chemokines (Figure 2).
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cules (D6; duffy antigen receptor for chemokines: DARC; CCX-
CKR; CCRL2; and possibly CXCR7) whose primary function
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Figure 2. Nonsignaling ‘‘Scavenger’’ Chemokine Receptor-like
Molecules Adjust the Chemokine Environment
In inflamed tissues, an immature dendritic cell (DC) encounters a high concen-
tration of chemokines (CCL3, CCL4, and CCL5) that all signal to CCR5 and
‘‘anchor’’ the cell in place while they process antigen and upregulate functions
associated with antigen presentation. During this time, D6, a nonsignaling
scavenger receptor on lymphatic endothelium, clears excess inflammatory
CC chemokines. After maturation, the DC downregulates CCR5, thereby
limiting signaling from CCL3, CCL4, and CCL5. The mature DC also upregu-
lates CCR7. At the same time, other leukocytes upregulate D6 and assist in
removing these inflammatory chemokines (but not the homeostatic chemokine
CCL21) from the environment. The culmination of reduced signaling from
inflammatory chemokines and suppressed signaling from inflammatory che-
mokines favors entry of the DC into the afferent lymphatic vessel, whose lumen
is decorated with CCL21. The DC will subsequently traffic to the draining
lymph node. As shown on the bottom, the lateral line primordium comprises
a population of cells, organized in a coherent linear aggregate, whose migra-
tion is mediated by chemokine CXCL12. Cells at the leading edge express
the signaling receptor CXCR4. Cells at the trailing edge express CXCR7 and
enhance gradient steepness by removing CXCL12.seems to be adjusting ambient concentrations of their chemo-
kine ligands (Locati et al., 2005; Mantovani et al., 2006). In
some cases, these receptor-like molecules do not signal by
the canonical GPCR pathways but rather internalize chemokines
either to translocate them elsewhere or to dispose of them. From
evaluation of chemokine receptor-deficient mice, it is now
apparent that the ‘‘signaling’’ receptors similarly modulate the
chemokine environment (Cardona et al., 2008; Mantovani and
Locati, 2008). This function of chemokine receptors will need
to be taken into account, as therapeutic chemokine receptor
blockade becomes a more prevalent treatment for disease
(Charo and Ransohoff, 2006).
The chemokine receptor-like molecules that lack G protein
coupling mediate important functions in chemokine biology
(Rot and von Andrian, 2004). By convention, these molecules,
which fail to mediate chemoattraction in vitro and do not
increase cytoplasmic calcium concentrations, are termed ‘‘non-
signaling’’ receptors, although they clearly couple the presence
of their ligands to cellular responses. The nonsignaling receptors
are closely related to chemokine receptors, being ‘‘seven-span-
ning’’ plasma membrane components. The best characterized
are DARC and D6, each of which efficiently binds and internal-
izes numerous chemokines. Expressed on postcapillary venular
endothelium, DARC supports leukocyte recruitment to tissues,
through binding inflammatory chemokines abluminally, and
internalizing them for transcytosis and immobilization on the
lumenal aspect of the capillary, to signal to rolling leukocytes
(Pruenster et al., 2009). Parenthetically, DARC has also been
widely studied for its role in Plasmodium vivax invasion of eryth-
rocytes (Horuk et al., 1993). On red cells, DARC has long been
proposed to carry out physiological scavenging of the unbound
plasma fraction of its approximate dozen of chemokine ligands.
This speculation was confirmed with the recent demonstration
that posttransfusion pulmonary inflammation is caused in part
by the loss of DARC’s scavenging activity on banked erythro-
cytes (Mangalmurti et al., 2009). DARC therefore plays an exqui-
sitely subtle role in inflammation, removing surplus plasma
chemokines that could mediate harmful, indiscriminate inflam-
mation, while orchestrating leukocyte entry into tissues har-
boring pathogens or sites of damage.
Encoded at human 3p21, near a cluster of chemokine receptor
genes, D6 binds at least 12 inflammatory CC chemokines, inter-
nalizes them, and targets them for degradation, through consti-
tutive recycling between plasma membrane and endocytic vesi-
cles at an extraordinarily rapid rate (Locati et al., 2005). D6 is
expressed constitutively on lymphatic endothelium and, induci-
bly, on leukocytes (Graham and McKimmie, 2006), and the func-
tional importance of D6 on leukocytes versus lymphatic endo-
thelium is an unresolved question (Graham and McKimmie,
2006). Topical phorbol ester or intradermal complete Freund’s
adjuvant (CFA) caused remarkably enhanced and sustained
inflammation of the skin of D6-deficient mice, because of persis-
tently elevated local chemokine concentrations (Martinez de la
Torre et al., 2005; Jamieson et al., 2005).
In this context, D6 is a ‘‘scavenger’’ receptor and plays amajor
anti-inflammatory role. Studies of autoimmune central nervous
system (CNS) inflammation frequently involve a disease model
termed experimental autoimmune encephalomyelitis (EAE).
A surrogate for the inflammatory aspect of the human disorderImmunity 31, November 20, 2009 ª2009 Elsevier Inc. 713
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tion with peptide fragments derived frommyelin proteins emulsi-
fied in powerful adjuvants. Mice thus immunized develop
CNS inflammation including hematogenous leukocyte infiltrates
accompanied by motor signs about 2 weeks after immunization.
We speculated that D6-deficient mice might show aworsened
course of EAE, if chemokine clearance from the CNS were
impaired. Unexpectedly, D6-deficient mice did not generate
efficient encephalitogenic responses to immunization with
MOG35-55 peptide-CFA (complete Freund’s adjuvant) and were
relatively resistant to EAE (Liu et al., 2006a), possibly because
dendritic cells (DCs) trying to access lymphatics were trapped
in the ‘‘hyperinflamed’’ immunization site. The role of D6 in immu-
nity might therefore be to remove inflammatory chemokines and
allow DCs exiting tissue to respond to homeostatic chemokine
present on the lymphatic endothelial lumen. It should be empha-
sized that the D6 story is far from complete: the functional signif-
icance of its expression on lymphatic endothelium and leuko-
cytes remains enigmatic, as does its physiological significance
in adjusting the chemokine environment in the diverse settings
(inflammation, cancer, pregnancy) in which it’s been accorded
physiological significance (Borroni et al., 2008, 2009; Martinez
de la Torre et al., 2007; Nibbs et al., 2007).
A unifying concept from studying DARC and D6, two non-
signaling receptors is that they exert uniquely disparate func-
tions by virtue of their expression on parenchymal or vascular
elements, as compared with their expression on circulating or
extravasated blood cells. A cardinal example is DARC, where
expression on postcapillary venules mediates one set of effects
while its presence on erythrocytes mediates separate and
distinct functions (Rot, 2005).
Chemokines in Disease Pathogenesis
The CNS is immune privileged by virtue of lacking resident DCs
(Galea et al., 2007). Equally important for the preservation of its
postmitotic and fragile cells, the CNS possesses attributes that
modify inflammation. These characteristics include the blood-
brain barrier (BBB) (Bechmann et al., 2007) and a tendency to
recruit hematogenous cells very carefully. Cell loss after admin-
istration of the excitotoxin kainic acid (KA) involves neuronal
necrosis and illustrates this principle: different to such injury in
peripheral tissues (where necrotic injury elicits a rapid cellular
response dominated by neutrophils), CNS leukocyte infiltrates
after KA appear after a delay and consist primarily of mononu-
clear phagocytes (Bell and Perry, 1995).
If we consider the phenomenon of stringent control over leuko-
cyte entry into the CNS (Engelhardt and Ransohoff, 2005) and
also take account of the importance of chemokines for speci-
ficity in leukocyte migration, it is not surprising that early efforts
in the field of ‘‘neurochemokinology’’ involved analysis of the
functions of chemokines and their receptors in leukocyte traf-
ficking to the inflamed CNS. Much of this work utilized the EAE
model of autoimmune inflammatory mechanisms, which are
believed to be implicated in MS.
Trafficking of some but not all blood-derived leukocyte cell
types to the inflamed CNS of animals with EAE and other model
conditions have been attributed to specific chemokines and
their receptors. Importantly, disruption of chemokine-mediated
leukocyte trafficking also alters disease expression (Proudfoot714 Immunity 31, November 20, 2009 ª2009 Elsevier Inc.et al., 2008; Dogan and Karpus, 2004). However, major issues
remain unresolved. Although T lymphocytes are required for
EAE pathogenesis, no chemokine receptor is known to play a
nonredundant, essential role for migration of CD4+ T lympho-
cytes to the CNS during EAE. Below are examples of current
knowledge of chemokine receptors that regulate the migration
of leukocyte populations to the inflamed CNS of mice with EAE
and other model disorders.
Monocytes accumulate in large numbers in the inflamed CNS
of mice with EAE and give rise to macrophages that carry out
diverse functions including directly damaging myelin and axons,
clearance of tissue debris, and production of cytokines. Macro-
phages are pathogenic in EAE as shown by depletion studies
(Brosnan et al., 1981). Monocytes that enter the CNS are Ly6Chi
(King et al., 2009) and belong to a monocyte subset that prefer-
entially uses CCR2 for trafficking to inflamed tissues (Geissmann
et al., 2003). Even with a potent immunization regimen, Ccl2/
mice with EAE exhibit extremely mild disease, with near-
complete lack of infiltrating monocytes, and minimal demyelin-
ation (Huang et al., 2001). CCR2 was identified as the receptor
responsible for CCL2 action in EAE (Fife et al., 2000; Izikson
et al., 2000). Immunization with thrice higher antigen concentra-
tions than conventionally used drove atypical neutrophilic EAE in
Ccr2/ mice, underlining the role of CCR2 for monocytic infil-
trates (Gaupp et al., 2003). Blocking CCR2 with neutralizing
antibodies also suppressed EAE, with particular efficacy for
relapsing disease (Mahad and Ransohoff, 2003). The clinical
importance of this work was suggested by reports of altered
concentrations of CCL2 in the CSF of MS patients. Specifically,
MS patients exhibited reduced amounts of CSF CCL2, particu-
larly during active disease, whereas most neuroinflammatory
diseases (such as viral encephalitis or HIV-associated dementia)
feature very high CSF CCL2 concentrations. In vitro studies sug-
gested that CCL2 in the CNS extracellular space (in equilibrium
with the CSF), might be consumed by CCR2+ migrating cells
(Mahad et al., 2006). By using a variety of additional models of
CNS inflammation and injury, it became evident that CCL2
signals to CCR2 to recruit monocytes to the inflamed CNS (Mild-
ner et al., 2007; Ransohoff, 2007).
NK cells mediate regulatory effects in EAE, as suggestedmore
than a decade ago, by the occurrence of greatly worsened EAE
in mice treated with depleting NK1.1 antibodies (Zhang et al.,
1997). Later experiments demonstrated that CX3CR1 was
essential for recruitment of NK cells (but not NKT cells, T lympho-
cytes, or monocytes) into EAE tissues (Huang et al., 2006; Shi
and Van Kaer, 2006). Mice lacking CX3CR1 developed EAE of
equivalent severity to mice depleted of NK cells by passive
immunization with NK1.1 antibodies. Interestingly, individuals
with MS had lower numbers of CX3CR1
+ NK cells than did rele-
vant controls, and there was a relationship between frequency of
circulating CX3CR1
+ NK cells and MS disease activity (Infante-
Duarte et al., 2005).
In many circumstances, neutrophils are poorly recruited to the
CNS parenchyma and monocytes seem to be preferred. At the
early phases of some EAE models, substantial numbers of
neutrophils are observed, and there is indirect evidence that
they exert a pathogenic function (McColl et al., 1998). Cxcr2/
mice were relatively refractory to developing EAE and neutro-
phils were not detected in the CNS of mutant mice after
Immunity
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type neutrophils rescued the ability of Cxcr2/ mice to exhibit
signs of EAE (Carlson et al., 2008).
Importantly several chemokine system elements studied in the
EAE system are homologous in humans and mice. For example,
human CXCR2 functions equivalently to the murine ortholog in
knockin mice (Mihara et al., 2005). Furthermore, chemokine
receptors are drug targets (Charo and Ransohoff, 2006). There-
fore, where appropriate, insights from this research might readily
be applied to treating human inflammatory CNS diseases such
as MS.
Chemokines in Development and Physiology
of the Nervous System
Beginning in 1998 (Ma et al., 1998; Zou et al., 1998; Tachibana
et al., 1998), it was discovered that mice lacking CXCR4 or its
ligand CXCL12 harbored extensive neurodevelopmental defects
(Li and Ransohoff, 2008), with prominent malpositioning of
neurons of the cerebellum, dentate gyrus, trigeminal ganglia,
dorsal root ganglia, and cortical interneurons as well as aberrant
initial trajectory of spinal motor axons (Lazarini et al., 2003).
Chemokine CXCL1, in the presence of PDGF, also shows stimu-
lated proliferation of a key population of glial cells, the oligoden-
drocyte progenitor cells (OPCs) (Robinson et al., 1998). It was
later found that CXCR2 and its ligand CXCL1 helped determine
both positioning and numbers of oligodendrocytes in the devel-
oping spinal cord, by acting as an ‘‘arrest receptor’’ and prolifer-
ative signal for OPCs (Tsai et al., 2002). These reports about
CXCR4’s actions toward neurons and the role of CXCR2 in glio-
genesis sparked reconsideration of contemporary phylogenetic
research, culminating in the proposal that CXC chemokines
emerged at the dawn of vertebrate evolution, to pattern the
nervous system (Huising et al., 2003).
In retrospect, it seems unsurprising that chemokines are
broadly involved in organ patterning. Chemokine receptors had
been shown to organize secondary lymphoid organs during
development (Forster et al., 1996). Further, chemokines and che-
mokine receptors can be identified in the most primitive verte-
brates, the agnathous fish Eptatretus burgeri (hagfish), but not
in invertebrates (DeVries et al., 2006).
Despite their function during development, it seems somewhat
perplexing that chemokine receptors are expressed on adult
neural cells and mediate physiological or repair functions in the
adult CNS (Imitola et al., 2004; Tran and Miller, 2003). However,
by analogy with the neurotrophins (Arevalo and Chao, 2005;
Chao et al., 2006; Zampieri and Chao, 2006), it seems that che-
mokines and their receptors play selected roles in nervous
system development and are then retained for distinct purposes
during postnatal and adult life. A first workshop on ‘‘Chemokines
and Chemokine Receptors in the Nervous System’’ (Trettel et al.,
2008) was held and addressed this topic among many others.
The most powerful means to localize a receptor in tissue is
through immunohistochemistry, which simultaneously reports
the presence of protein, its cell of origin, and its subcellular
localization. Sadly, production of specific and sensitive anti-
bodies to chemokine receptors has proven difficult. As a result,
many preliminary reports using immunohistochemistry to
analyze chemokine receptor expression by CNS cells could
not be confirmed by definitive studies that included evaluationof wild-type and gene-deficient mice. Standards for CNS tissue
immunohistochemistry have been proposed and it would be
prudent to regard reports using immunohistochemistry to
describe chemokine receptors in CNS tissues as preliminary
until all criteria enunciated therein have been fulfilled (Saper
and Sawchenko, 2003).
In several cases, chemokine receptors can be found both on
circulating leukocytes and on parenchymal cells of the CNS,
including neuroepithelial cells. In such cases, four of which are
illustrated below, potentially decisive roles are played by these
receptors and their ligands in neuroinflammatory processes.
This attributemakes these chemokine-receptor pairs particularly
worthy of attention for neuroimmunologists and neuroinflamma-
tion researchers.
CXCR4 has been termed the ‘‘ancestral chemokine receptor’’
because its homologs are most readily identified in phylogenetic
studies of chemokine receptors. The unique ligand for CXCR4 is
CXCL12, and the pair was considered monogamous until recent
reports that characterized RDC1 (an orphan GPCR) as CXCR7,
the second CXCL12 receptor (Sierro et al., 2007; Burns et al.,
2006).
Along with showing the earliest expression of any chemokine
system elements during embryogenesis, the CXCR4-CXCL12
signaling pair has a large array of developmental functions.
These properties seem most pertinent for development of the
cardiovascular, hematopoietic, nervous, and urogenital sys-
tems, all of which show abnormalities in the mice. During adult
life, CXCR4 is expressed on circulating lymphocytes, neutro-
phils, and monocytes. CXCR4 does not seem, however, to regu-
late leukocyte accumulation in tissues but does play a role in
lymphocyte trafficking within lymph nodes (Okada et al., 2002).
Interestingly, distribution of cells within inflamed CNS lesions is
in part modulated by interactions between CXCL12, which is
normally immobilized at the abluminal surface of cerebral micro-
vessels, andCXCR4 on leukocytes, which are thereby retained in
perivascular spaces (McCandless et al., 2006, 2008b). There is
preliminary evidence that these observations might be pertinent
for human disease (Moll et al., 2009; McCandless et al., 2008a).
Studies of CXCR4 in zebrafish nervous system development
provided results that exemplified how decoy receptors might
shape chemokine gradients to optimize migratory competence.
During zebrafish embryogenesis, approximately 100 migrating
cells constitute the primordium that will give rise to posterior
lateral line neurons that sense water currents. These cells
migrate with anterior-posterior directionality, in a uniform con-
centration of SDF1a, a CXCL12 homolog. Cells at the leading
edge of themigrating cell band express CXCR4b, whereas those
at the trailing border express CXCR7. Antisense-mediated
knockdown of either CXCR4b or CXCR7 partially impairs migra-
tion. Suppression of the CXCL12a ligand, or of both receptors,
produces marked defects in migration, halting the primordium.
One interpretation (Dambly-Chaudiere et al., 2007) of these find-
ings is that CXCR4b is the signaling receptor for migration,
whereas CXCR7 internalizes ligand and establishes the chemo-
kine gradient (Figure 2; Tiveron and Cremer, 2008). These find-
ings illustrate a principle of chemokine action: that nonsignaling
receptors can assist in generating chemokine gradients for
migration. Applications of these insights to mammalian neuro-
chemokinology are eagerly awaited.Immunity 31, November 20, 2009 ª2009 Elsevier Inc. 715
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expression on a large proportion of tissue stem cells. For
example, mobilization of CD34+ hematopoietic stem cells from
bone marrow stores can be mediated directly by pharmacolog-
ical blockade of CXCR4 with AMD3100, one of two FDA-
approved drugs targeting chemokine receptors. In the postnatal
CNS, CXCR4 functions include modulating GABAergic inputs to
dentate gyrus neural progenitor cells, thereby providing regula-
tory control over proliferation during adult neurogenesis (Bhatta-
charyya et al., 2008; Kolodziej et al., 2008). These two functions
could not be more dissimilar and incarnate the diverse functions
of chemokines and chemokine receptors in the nervous and
immune systems.
A final neurobiological function of postnatal CXCR4-CXCL12
concerns two relatively new concepts: first, that of gliotransmit-
ters, by which astrocytes participate actively in synaptic trans-
mission (Chen et al., 2006); and second that cytokine TNFa
also functions physiologically at CNS synapses (Stellwagen
and Malenka, 2006). In an elegant series of studies (Bezzi
et al., 2001; Cali et al., 2008), it has been shown that CXCL12
signaling to CXCR4modulates astrocyte exocytosis of the excit-
atory neurotransmitter glutamate and that subsequent signaling
elicits rapid release of TNFa. Thismechanism cleverly uses avail-
able materials to support normal synaptic physiology but carries
hidden dangers (Allen and Attwell, 2001). If nearby microglia that
also express CXCR4 and TNF receptors, respond to these prod-
ucts with augmented TNF release, neuronal damage can ensue,
both because of direct toxic effects of TNF and by virtue of
impaired astrocyte uptake of glutamate which, present in
excess, can engage a neurotoxic process termed excitotoxicity.
Chemokines received their initial attention because their index
member CXCL8-IL8 was the first leukocyte chemoattractant that
could signal to neutrophils and not tomonocytes, unlike classical
chemoattractants such as the complement anaphylatoxin C5a
(Ransohoff, 2005). One neutrophil receptor for CXCL8, desig-
nated CXCR2, was among the first to be cloned and deleted
from the murine genome (Cacalano et al., 1994). Of the CXCR2
ligands, CXCL1 (also known as GRO-alpha) has the most exten-
sively documented biology. This peptide has been discovered
and rediscovered in contexts as varied as inflammation (Reuter-
shan, 2006), cancer biology (Anisowicz et al., 1987; Luan et al.,
1997; Acosta et al., 2008), cell proliferation (Cochran et al.,
1983), wound healing (Martins-Green and Hanafusa, 1997),
angiogenesis (Strieter et al., 2004), and neuroglial cell biology
(Tran and Miller, 2003).
The exceptional versatility of CXCR2 is best shown through
its implication in cutaneous wound healing (Devalaraja et al.,
2000; Milatovic et al., 2003). When full-thickness skin lesions
were characterized in Cxcr2/ mice, the data suggested that
CXCR2 was responsible for (1) attracting neutrophils into the
skin breach; (2) promoting angiogenesis through expression on
angioblasts; and (3) fostering epithelialization via its presence
on keratinocytes (Zaja-Milatovic and Richmond, 2008). This
concerted action toward mesenchymal, hematopoietic, and
epithelial cells during a single tissue repair process lasting only
several days is unprecedented in chemokine biology.
Initial studies of oligodendroglial progenitors, purified from
neonatal rodent spinal cord, showed that CXCL1, although
devoid of intrinsic mitogenic properties, could synergize with716 Immunity 31, November 20, 2009 ª2009 Elsevier Inc.platelet-derived growth factor (PDGF) to drive a 4-fold increased
proliferative response as compared with PDGF alone (Robinson
et al., 1998). Further evaluation in immediately postnatal mice
revealed that migrating oligodendrocyte progenitor cells (OPCs)
encountered a locally elevated concentration of CXCL1 in the
terrain destined to give rise to ventral spinal cord white matter.
A combination of assays including in vitro migration studies
and slice culture preparations showed that CXCL1 enhanced
the interactions between migrating OPCs and the tissue
substrate, leading to stalled movement (Figure 1). At the site of
arrest, OPCs found themselves in high concentrations of both
CXCL1 and PDGF, proliferated vigorously, then differentiated
and myelinated axons (Tsai et al., 2002; Tran and Miller, 2003).
Ventral CXCL1 expression receded during the first postnatal
week, to be succeeded by dorsal CXCL1 production, which
promoted myelination of this portion of the spinal cord during
the second postnatal week. Mice lacking CXCR2 exhibited
a somewhat predictable phenotype: migrating OPCs failed to
arrest in the presumptive white matter and accumulated at the
tissue edge, the pial surface of the developing spinal cord.
Because these misplaced OPCs found axons in a dysregulated
sequence, early myelin formation was shifted from the white
matter toward the pial surface, and the normal G-ratio, which
expresses the tight relationship between axon caliber andmyelin
thickness, was perturbed (Padovani-Claudio et al., 2006).
As noted above, the presence of CXCR2+ neutrophils was
sufficient to render Ccxr2/ mice susceptible to EAE (Carlson
et al., 2008). Notably, however, resultant disease was mild,
raising the question whether other effects of CXCL1 and CXCR2
might be involved in disease severity (Omari et al., 2009). The
components of the CXCR2-CXCL1 signaling system are present
in the CNS of mice with EAE and humans with MS (Omari et al.,
2005, 2006; Glabinski et al., 1997). Furthermore, an excess of
CXCL1 in transgenicmice appears tomodulate disease, although
the mechanism for this effect remains uncertain (Omari et al.,
2009). Further studies of genetic and disease models may help
to clarify the specific functions of CXCR2 and its ligands during
inflammatory demyelination and other disease states.
CX3CR1 and Fractalkine: Location, Location, Location
CX3CL1 (also known as fractalkine) has been fascinating and
frustrating researchers since its first description (Schall, 1997).
Fractalkine is an unusual chemokine, one of two expressed as
a primary single-pass transmembrane molecule that is capable
of mediating firm monocyte-endothelial adhesion under flow,
or chemoattraction, after proteolytic release. Fractalkine’s func-
tion toward circulating monocytes has become increasingly
clear because of convergent lines of investigation. Mutant mice
(Cx3cr1/) were shown to have lessened atherosclerosis
because of reduced monocyte infiltration of atheromata, in rele-
vant models (Charo, 2001; Lesnik et al., 2003). Adding spice to
the story, humans (about 30% of the Caucasian population)
with a variant form of the receptor that blunted adhesive sig-
naling, also showed delayed atherosclerotic endpoints (McDer-
mott et al., 2001, 2003; Moatti et al., 2001). Another contribution
to understanding fractalkine biology came from delineating two
subsets of circulating monocytes, one of which expressed low
levels of Ly6C but high levels of CX3CR1 (Geissmann et al.,
2003, 2008).
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Figure 3. Differential Expression and
Function of CX3CL1 in the Peripheral
Vasculature and Central nervous System
In the periphery (upper panel), fractalkine is ex-
pressed on the endothelium as a single-pass
transmembrane component, which can mediate
firm arrest under flow. Ly6Clo monocytes express
high amounts of CX3CR1 receptor and can be
recruited into a developing atheroma through
CX3CL1-CX3CR1 interactions. Both Cx3cr1
/
mice and individuals harboring a polymorphic
variant of CX3CR1, CX3CR1
I249/M280, which acts
as a dominant negative inhibitor of signaling, are
relatively protected from atherosclerosis. Athero-
mata are also infiltrated by Ly6Chi monocytes via
signaling to CCR2. As shown in the bottom panel,
fractalkine is not present on CNS vessels. Instead,
fractalkine is expressed by neurons, in which it can
be cleaved and released by ADAM proteases,
so that the healthy adult mouse brain contains
150–300 pg/mg protein of soluble fractalkine.
Microglia uniformly express CX3CR1 and respond
to ligand by modulating effector functions in
a manner that modulates toxicity to neurons. Indi-
viduals bearing the CX3CR1
I249/M280 variant are at
increased risk for age-related macular degenera-
tion (AMD), an inflammatory neurodegenerative
disorder, possibly because of neurotoxicity medi-
ated by retinal microglia.The distinct role of CX3CR1 in the CNS arises from the expres-
sion pattern of the ligand (Figure 3). In particular, vascular struc-
tures (endothelial or smooth muscle cells) expresses fractalkine
except within the CNS (Sunnemark et al., 2005), where fractal-
kine is produced by neurons (Harrison et al., 1998). Neurons
constitutively produce substantial amounts of soluble fractalkine
through ongoing transcription, membrane insertion, and proteo-
lytic release (Cardona et al., 2008). The fractalkine receptor
CX3CR1 is present in the CNS only on microglia (Cardona
et al., 2006). Evaluation of several pathological processes that
did not involve BBB compromise (and therefore did not entail
large-scale entry of peripheral leukocytes) showed that signaling
through the fractalkine receptor reduced neuronal damage (Car-
dona et al., 2006). One potential mechanism for this protective
effect was demonstrated in vitro: microglia exposed to fractal-
kine produce adenosine that signals to protect hippocampal
neurons from excitotoxic challenge, through the A1 receptor
(Lauro et al., 2008). The potential practical relevance of fractal-
kine’s ability to inhibit microglial neurotoxicity was illustrated
vividly by increased liability to age-related macular degeneration
in individuals expressing the variant form of the receptor (Com-
badiere et al., 2007; Tuo et al., 2004).
CCR2 and CCL2: Multiple Roles in Pain States
As noted above, CCR2 is expressed by a subpopulation of
monocytes that are typified by the presence of high amounts
ofmembrane Ly6C, and CCR2 is required for entry of monocytes
into diverse inflammatory sites including the CNS (Charo and
Ransohoff, 2006). CCL2 is the principal ligand for trafficking of
CCR2+ ‘‘inflammatory’’ monocytes into the nervous system(Mahad et al., 2006). Mice lacking CCR2 and CCL2 were
produced in the late 1990s and were both viable and fertile,
with their study yielding remarkable insights into their biology
(Charo and Peters, 2003; Gu et al., 1999). Subsequent studies
showed potentially distinctive roles for CCR2 and themonocytes
whose function it governed, in models of Alzheimer’s disease
and age-related macular degeneration (El et al., 2007; Ambati
et al., 2003). Ccr2/ mice were resistant to models of pain
(Abbadie et al., 2003) and, remarkably, both inflammatory pain
(elicited by injecting irritants) and neuropathic pain (induced by
nerve injury) were about equally affected. Initial evaluation of
the affected tissues demonstrated upregulation of CCR2 in the
dorsal root ganglia (DRG), in the injured nerve and in the inflamed
injection site. It seemed plausible that pain pathways were
modulated by the presence of CCR2+ inflammatory monocytes
and that loss of CCR2 signaling ameliorated pain by dampening
macrophage-mediated inflammation. Concordant results were
obtained through study of transgenic mice that overexpressed
CCL2 in the CNS under control of the astrocyte-specific GFAP
promoter (Menetski et al., 2007).
However, the situation became more complex with the
surprising demonstration that DRG neurons upregulated both
ligand CCL2 and receptor CCR2 in the context of chronic nerve
root damage. Furthermore, CCL2 was packaged in synaptic-like
vesicles and its action at CCR2 led to pain-promoting responses,
including sensitization of the transient receptor potential vanilloid
receptor subtype 1 (TRPV1) ion channel (Jung et al., 2008; White
et al., 2005; White and Wilson, 2008). Taken together, these
results indicate that CCR2 plays a complex, multifarious role in
pain states, both through its expected function on inflammatoryImmunity 31, November 20, 2009 ª2009 Elsevier Inc. 717
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Reviewmonocytes and via its startling and novel properties as an
inducible neuromodulatory receptor on DRG neurons (Abbadie,
2005).
Concluding Remarks
From the perspective of neuroinflammation studies, chemokine
research has followed a long and complex odyssey beginning
with subset-specific chemoattractants, which seemed likely to
mediate the cautious recruitment of leukocytes into the CNS
and PNS. Along the way, chemokine receptors were discovered
on neural cells, and other CNS-resident cells were shown
capable of elaborating chemokine ligands. With the recognition
that chemokines and their receptors on these diverse cell types
can interact during pathological processes, bewildering and
tantalizing vistas of cross-system signaling between the CNS
and the immune system become apparent. Deciphering this
signaling will place researchers in a position to deploy their
insights in the service of novel strategies to treat neurological
disease.
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